French health authorities have announced the full availability of the Shingrix vaccine as of January 7, 2026, following a period where supply was closely monitored.The vaccine is crucial for preventing shingles, a painful condition affecting a significant portion of the population, and the related complication of postherpetic neuralgia. This news will be especially welcomed by those aged 50 and over, and individuals with increased risk factors, for whom Shingrix is recommended. The agence nationale du médicament et des produits de santé (ANSM) advises adherence to official vaccination guidelines.
mesvaccins.net
The Shingrix vaccine, used to prevent shingles and postherpetic neuralgia, is once again fully available, according to a notice released by the French National Agency for the Safety of Medicines and Health Products (ANSM) on January 7, 2026. This news comes as healthcare providers and patients alike closely monitor vaccine supplies amid ongoing public health concerns.
Shingrix is indicated for the prevention of shingles and the associated complication of postherpetic neuralgia (PHN) in adults aged 50 years and older, as well as in adults 18 years and older who are at an increased risk of contracting the disease. The ANSM advises that the vaccine should be administered in accordance with official recommendations.
The vaccine is a recombinant subunit vaccine with adjuvant, designed to boost the immune system’s response to the varicella-zoster virus, which causes shingles. More information about Shingrix can be found on mesvaccins.net.
The ANSM’s announcement signals a return to normal distribution levels after a period of potential supply constraints. Details regarding the reason for the previous disruption were not disclosed by the agency, but the restoration of full availability is expected to alleviate concerns for those eligible for vaccination. You can find the original announcement from the Agence nationale du médicament et des produits de santé.
Zones Associées: France
